Phase 3 Stroke Trial, Recruiting NCT06360120 Sponsor: Kafrelsheikh University Condition: Stroke
Back to Stroke

Phase 3 Stroke Trial, Recruiting

NCT06360120
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 75 years old (male or female)
  • People who have had their first-ever stroke caused by a blockage in a large blood vessel in the brain

Who may not be able to join:

  • People who have a known allergy to any of the medications being studied in the trial
  • People who had seizures as part of their stroke
  • People with major failure of a vital organ (such as the heart, liver, or kidneys)
  • People who have been diagnosed with cancer
  • People who had a heart attack in the six weeks before joining
  • People who took blood-thinning or anti-clotting medications in the week before joining
  • People whose stroke was very mild (a score of 3 or lower on a standard stroke severity scale) or very severe (a score of 25 or higher on that same scale)
  • People whose stroke symptoms went away on their own before brain imaging was done
  • People with a pre-existing brain or nervous system condition, such as multiple sclerosis, epilepsy, or a type of brain tumour called meningioma
  • People for whom surgery to clear blockages in the neck, brain, or heart arteries was already planned within seven days of joining the trial
  • People who had a stroke caused by a blood clot travelling from the heart, either before or after treatment — including people with conditions such as atrial fibrillation, certain heart valve problems, or a hole in the heart
  • People diagnosed with atrial fibrillation (an irregular heart rhythm) based on a standard heart tracing test
  • People with a condition that could cause bleeding in the stomach or gut, such as a stomach ulcer
  • People who have had a previous stroke
  • People with blood sugar levels that are too low (below 50 mg/dL) or too high (above 400 mg/dL) at the time of joining
  • People with abnormal blood clotting results or a low platelet count (confirm with trial site for exact values)
  • People who regularly take certain medications that affect how the body processes a drug called clopidogrel — including some heartburn medications (proton pump inhibitors), ketoconazole (an antifungal), certain blood pressure medications (dihydropyridine calcium channel blockers), or rifampin (an antibiotic)
  • People who are pregnant or breastfeeding
  • People whose stroke involved a blocked vein rather than a blocked artery in the brain
  • People whose stroke was caused by reduced blood flow rather than a direct blockage

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: mohamed G. Zeinhom, MD, neurology department kafr el-sheikh university

Phone: 2001009606828

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Kafrelsheikh University
Registry
ClinicalTrials.gov
Start date
10 April 2024
Est. completion
10 September 2025

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

the rate of new stroke at 90 days

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov